MEDI-7526

N/A

Report date: 2022/06/17 16:22:43

Base Information

Drug NameMEDI-7526

Drug Alias NameMEDI-7526

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCD40 ligand stimulantsT lymphocytes stimulants +[4]

TargetsProgrammed death-ligand 1CD40 ligand

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAstrazeneca Turkey

China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Turkey

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A